Interestingly, analysis of a series of cancer types that harbored aberrant RAS and/or RAF mutations as oncogenic drivers indicated that the expression of GRB7 in lung carcinoma and pancreatic cancer was much higher than that in melanoma (Supplementary Fig. S2). Here, GRB7 is linked to familial pancreatic carcinoma.